Free Republic

November 25, 2009 --From yesterday's Associated Press: "Demand for gold held up as investors looked for safe places to park their cash. Gold is seen as both an alternative to a weak dollar and a safe-haven investment because of its stable store of value. That has helped drive gold prices to record highs this year." This pre-Thanksgiving period seems more important than any other I can remember. The place where I park is empty, meaning that everybody has high-tailed it out of town. I note that the Christmas signs are up already -- lights, sales ads, reminders. Long ago I...

Lately there has been a big increase in speculation about an official revaluation of gold. At YouTube this week Rebel Capitalist's George Gammon seemed surprised by the possibility as he called attention to financial letter writer Luke Gromen's recent report that the May edition of the Federal Reserve's Financial Accounting Manual for Federal Reserve Banks describes a mechanism by which the U.S. Treasury Department and the Fed can revalue the U.S. gold reserve: https://www.youtube.com/live/oDNhrvbZV34 While this was news to Gammon, revaluation is an old story with gold. Gromen actually disclosed the mechanism in the Fed manual last year -- https://www.gata.org/node/23332...

Dear Friend of GATA and Gold: In this week's edition of Kinesis Money's "Live from the Vault" program, London metals trader Andrew Maguire outlines what he says are the many bullish drivers of the gold price. He says Chinese central bank buying remained strong this week though retail buying was absent because of the "Golden Week" holidays. Indian central bank buying remained strong as well, Maguire says. Using price charts, Maguire says central bank buying is steadily driving up the gold price in calculated stair steps that prevent the physical market from becoming too disorderly. Now that the BRICs nations...

Gilead Sciences' (GILD) Sovaldi is now projected to become the best-selling medicine of all time by several analysts. Sovaldi is the first in a new wave of Hep C treatments that promise better cure rates and a shorter treatment course. Some even forecast it would reach $9 billion or more in sales by 2017, at which level it would surpass Pfizer's (PFE) Lipitor and take the crown as the biggest-selling drug of all time. Analysts are trying to outdo each other with optimistic forecasts. According to ISI Group analyst Mark Schoenebaum, if prescriptions were to never grow again, that is...